What's new?
27/09/2017

Paris, France – September 27th, 2017 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Henrijette Richter as Managing Partner. She joins Antoine Papiernik, Denis Lucquin, Graziano Seghezzi and Monique Saulnier in the company’s Managing Partnership. With a 14 years’ experience in venture capital, Henrijette brings her extensive industry experience and strong international network to Sofinnova Partners’ leadership.

Henrijette joined Sofinnova Partners in October 2014, after seven years at Novo Holdings A/S (the holding company in the Novo Group) where she co-founded Novo Seeds. Prior to that, she worked at Sunstone Capital and was part of the founding team when the fund spun out of The Danish Growth Foundation. Henrijette is a scientist by training, she holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen, and did her postdoctoral fellowship at MIT Center for Cancer Research, Cambridge, MA.

Since 2014, Henrijette has lead key investments such as in Asceneuron, a biotech company specialized in neurodegenerative diseases headquartered in Switzerland where she also serves on the Board of Directors. Henrijette also seeded and invested in Delinia, a US-based company specialized in the treatment of auto-immune disorders that was sold to Celgene Corporation in January 2017 for a total value of up to $775 M.

Henrijette Richter says: « I am honored by this new role and excited to take a more active role in Sofinnova Partners’ growth strategy to reinforce its global leadership in Life Sciences. I have the foremost respect for the team, its values, the culture of diversity, and the entrepreneur-oriented spirit it has been fostering worldwide for more than forty years ».

Antoine Papiernik, Chairman of Sofinnova Partners, adds: « Henrijette stands out for her investment track record and has demonstrated impressive team leading skills. She is a great addition to our team, and we are extremely pleased to welcome her to the Managing Partnership as Sofinnova Partners is entering a new phase of its development ».
Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

30/06/2003
17/06/2003
05/06/2003

 

05/06/2003

 

05/06/2003
14/05/2003
02/05/2003
28/04/2003
17/04/2003

Diatos SA, a privately held biopharmaceutical company that develops novel therapeutics based on its innovative drug-targeting (TSP) and intracellular-delivery (DPV) technologies, announced today the appointments of Denis Ravel, Ph.D., to the position of Chief R&D Officer, and Sandrine Leonardi to the position of Finance Director. With these appointments Diatos has completed its core management team.

Dr. Ravel brings 18 years of experience in the biotechnology and pharmaceutical industry with extensive background in preclinical and early clinical development of new drugs in the field of metabolic diseases. Prior to joining Diatos, Dr. Ravel was Director of Pharmaceutical Development at Genset and in charge of the Genset San Diego Research Center. In his position at Genset, he led the preclinical development of Famoxin [APM-1], a recombinant protein with anti-diabetic activities. Prior to joining Genset in 2001, Dr Ravel worked for 16 years at Servier, as Senior Pharmacologist and as Project Manager of preclinical and early clinical Drug Development before being promoted to Head of Department. Dr. Ravel obtained a Ph.D. in Biochemistry from Université Pierre et Marie Curie, Paris, France, in 1983.

Sandrine Leonardi joins Diatos from ifrance (a VU group company) where she was Finance Director of the French company and its Spanish subsidiary (iespana). Ms. Leonardi’s prior positions include being Finance Controller Europe of Louis Vuitton Malletier and Head of Financial Control for Europe 2 Communication. Ms. Leonardi graduated from HEC, a leading French Business School, Paris, France, in 1992, and obtained a Masters in Political Science from Columbia University, New-York, USA, in 1993.

"We are pleased to have executives with Denis’s and Sandrine’s experience join our fast-growing company," said Dr John Tchelingerian, President and CEO of Diatos. "Denis’s experience in pharmaceutical development will be extremely valuable as we advance our pipeline of therapeutic products through preclinical and clinical development."

Contacts: Diatos
Dr. John Tchelingerian, President and CEO
Tel: +33 1 53 80 93 81
jtchelingerian@diatos.com

About Diatos
Diatos is a privately held biopharmaceutical company that uses its proprietary drug-targeting and intracellular-delivery technologies to develop innovative therapies for cancer and other serious diseases. Diatos has two core technology platforms:

Diatos Peptide Vector (DPV) technology enables or significantly enhances selective cellular or nuclear uptake of a broad range of therapeutic compounds, including small molecules, peptides and proteins, antibodies and antibody fragments, oligonucleotides, and nanospheres.

Tumor Selective Prodrug (TSP) technology enables the release of anti-cancer agents selectively at the sites of tumor cells.

In addition to using these technologies to develop its own product pipeline, Diatos is offering these technologies to pharmaceutical and biotechnology companies, under licensing or partnering relationships, for the development of a broad range of therapeutic products in various therapeutic fields and for target validation and drug screening.

Founded in 1999 as a spin-off from Institut Pasteur, Diatos has raised to date 23.5 Million Euros. Diatos has a total of 40 employees at its headquarters in Paris, France, and at the campus of Louvain-la-Neuve Université in Louvain, Belgium.

20/03/2003

Over 40 CEOs from Europe and the US came together on the island of Corsica for a trans-Atlantic meeting of the minds


We’re pleased to announce that we recently held our inaugural Sofinnova CEO Conference, which we co-hosted with Sofinnova Ventures of San Francisco from March 20-22. Our goal was to provide our CEOs with constructive and thought-provoking workshops, as well as the opportunity to network with an international peer group. The conference brought unique trans-Atlantic value to our portfolio companies.


The event was a real success. Despite the coinciding outbreak of war, 43 CEOs from Europe and the US flew to Corsica to attend the 2-day event. Special guests who addressed the group included information technology keynote Jean-Francois Pontal, CEO of European telecommunications giant Orange SA; life science keynote Jean-Pierre Garnier, CEO of GlaxoSmithKline; Ken Alwyn, a senior partner in PricewaterhouseCoopers’ global organization; and Marco Landi, former president of BMC Europe, former COO of Apple Computer and former president of Texas Instruments Europe.


The CEOs discussed their business challenges and shared best practices regarding critical business issues such as surviving in an adverse economic environment, development of a global strategy, strategic business plan development, optimal sales force management, development of a customer-focused organization, corporate governance, and, of course, “managing your board.”
We will host CEO conferences annually, alternating the locale between Europe and the U.S.